Search results
Hedgehog Pathway Inhibitor Improves IPF
Medscape· 1 day agoPatients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of...
PFF Community Registry Reaches Milestone of 2,000 Participants Impacted by Pulmonary Fibrosis and...
WROC Rochester· 21 hours agoAchieving a significant milestone, the Pulmonary Fibrosis Foundation (PFF) Community Registry has reached 2,000 participants and counting, providing researchers ...
... 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with...
Digital Journal· 24 hours agoStockholm, May 20, 2024- Vicore Pharma Holding AB (STO: VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor ...
Vicore's bet pays off as pulmonary fibrosis drug improves lung function in phase 2
FierceBiotech· 1 day agoHaving stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid,...
Council Post: Go Forth, And Fight Aging
Forbes· 7 hours agoRecently, he shared a paper in Nature Biotechnology with his hundreds of thousands of Twitter followers about a new drug, designed by AI, for the rare...
Endeavor BioMedicines' ENV-101 improves lung function and reverses fibrosis in IPF patients
BioPharma-Reporter· 1 day agoThe treatment showed improved lung function and reversed lung fibrosis in idiopathic pulmonary ...
Once-Promising Drug for Idiopathic Pulmonary Fibrosis Fails in Phase III Trial
MedPage Today· 1 day agoThe fully human monoclonal antibody pamrevlumab failed to improve lung function among patients with idiopathic pulmonary fibrosis (IPF) in the randomized ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 16 hours agoAP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations Highlighted Post-hoc Analyses of the ATLAS
Taking on pharma giants, Endeavor links IPF drug to improved lung function in phase 2
FierceBiotech· 1 day agoEndeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic ...
Endeavor’s ENV-101 improves lung function in Phase IIa IPF trial
Clinical Trials Arena via Yahoo Finance· 1 day agoEndeavor BioMedicines has revealed results from the Phase IIa clinical trial where ENV-101...
